Healthcare

AstraZeneca and Oracle partner on AI-powered clinical trials and patient care

AstraZeneca and Oracle are partnering with M42 on AI-supported hypertension diagnosis, clinical-trial recruitment, and patient-care initiatives in Abu Dhabi.

AstraZeneca and Oracle announced a collaboration using artificial intelligence and real-world healthcare data to improve clinical-trial recruitment, earlier diagnosis, drug-safety monitoring, and patient care. The first program will focus on hypertension in Abu Dhabi and will involve M42. The initiative is intended to identify patients with uncontrolled hypertension, support guideline-based treatment, and connect eligible patients with clinical trials. Further projects are planned across the United States, Europe, and the Middle East.

Original source: EMEA Outlook

Related RAQI solutions

In-depth analysis on RAQI Insight

Work with RAQI